The University of Southampton
University of Southampton Institutional Repository

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer
PURPOSE: To analyze the baseline clinicopathologic characteristics of prostate tumors with germline BRCA1 and BRCA2 (BRCA1/2) mutations and the prognostic value of those mutations on prostate cancer (PCa) outcomes.

PATIENTS AND METHODS: This study analyzed the tumor features and outcomes of 2,019 patients with PCa (18 BRCA1 carriers, 61 BRCA2 carriers, and 1,940 noncarriers). The Kaplan-Meier method and Cox regression analysis were used to evaluate the associations between BRCA1/2 status and other PCa prognostic factors with overall survival (OS), cause-specific OS (CSS), CSS in localized PCa (CSS_M0), metastasis-free survival (MFS), and CSS from metastasis (CSS_M1).

RESULTS: PCa with germline BRCA1/2 mutations were more frequently associated with Gleason ? 8 (P = .00003), T3/T4 stage (P = .003), nodal involvement (P = .00005), and metastases at diagnosis (P = .005) than PCa in noncarriers. CSS was significantly longer in noncarriers than in carriers (15.7 v 8.6 years, multivariable analyses [MVA] P = .015; hazard ratio [HR] = 1.8). For localized PCa, 5-year CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93% v 77%; MVA P = .009; HR = 2.7, respectively). Subgroup analyses confirmed the poor outcomes in BRCA2 patients, whereas the role of BRCA1 was not well defined due to the limited size and follow-up in this subgroup.

CONCLUSION: Our results confirm that BRCA1/2 mutations confer a more aggressive PCa phenotype with a higher probability of nodal involvement and distant metastasis. BRCA mutations are associated with poor survival outcomes and this should be considered for tailoring clinical management of these patients.
1527-7755
1748-1757
Castro, E.
a0e345ca-5a05-4fea-86c5-c2c48808c1bc
Goh, C.
04866191-966e-4d2a-aed5-5d7d269c410f
Olmos, D.
23057019-96bf-461f-9cd4-e3444f0a612e
Saunders, E.
71c86362-6926-4b2b-a8a2-07bb7617b4fa
Leongamornlert, D.
f4befc93-162d-48ba-a3db-a8954813ea64
Tymrakiewicz, M.
4179a470-13cd-47d6-a6e8-c17f6cb74618
Mahmud, N.
96b3afae-fd67-419b-9028-9d6993eeb734
Dadaev, T.
6b95b313-75f2-4e4d-9dbe-32f473df0ba7
Govindasami, K.
f6e4500c-d867-4067-b441-c3a6b5855217
Guy, M.
682e7cb4-f2b7-457c-ba8a-efa0155a918f
Sawyer, E.
e3ad320a-b2c4-4abf-802f-744ab07a65bc
Wilkinson, R.
93d60b91-c9fc-4de3-929b-cebbb412ee1a
Ardern-Jones, A.
615ce40c-596a-4b29-9578-13bf644aa3e0
Ellis, S.
e52868aa-0957-4f09-aa93-2bcd8ee03cfc
Frost, D.
aacda8ac-d343-4d95-a2d4-5c95a98072f2
Peock, S.
078d7af2-b419-40af-a52d-df59456d03b3
Evans, D.G.
b58c99fc-4da0-4d7e-b140-f22307befe5e
Tischkowitz, M.
d479aaea-0e4f-4f55-bc25-25fb599e7668
Cole, T.
5330af8b-76ec-4957-87b2-3aa3580a74c0
Davidson, R.
9f684474-a989-4d8c-988c-a42e3d19db25
Eccles, D.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Brewer, C.
f50e5721-93d3-43ef-8cd2-572f238d04be
Douglas, F.
9dc3db90-827e-419d-86f1-48e22b6845ab
Porteous, M.E.
e9bac242-13be-4b4b-bb8c-5ac6b8835e8c
Donaldson, A.
ea10ac5a-4f77-4ef5-91d5-7f32ea33db36
Dorkins, H.
c5c983b7-709c-4580-b98c-771a57aa31f0
Izatt, L.
5cabcdef-374a-4441-b571-9c7b1665b720
Cook, J.
45c40993-978e-496e-9922-65774f13985e
Hodgson, S.
745600cf-b91f-4f39-9b5e-4f76989d268f
Kennedy, M.J.
617fefc1-ee68-48ca-9fd6-66ef3733b442
Side, L.E.
35b06306-9246-4d20-887a-4472912fcf11
Eason, J.
8259442f-7b72-4b76-9a30-fa549384bbe0
Murray, A.
d80b2bea-5bde-448f-a1d2-c5627db1df99
Antoniou, A.C.
6dc040a0-bd30-4178-995b-ca6f237949e1
Easton, D.F.
ef4b7694-86fa-4568-969f-d0ee512127fc
Kote-Jarai, Z.
2d7fe076-52c9-4d83-b780-e85f8660ef05
Eeles, R.
c7ae2359-6f49-4f42-88f8-a241570f9d4f
Castro, E.
a0e345ca-5a05-4fea-86c5-c2c48808c1bc
Goh, C.
04866191-966e-4d2a-aed5-5d7d269c410f
Olmos, D.
23057019-96bf-461f-9cd4-e3444f0a612e
Saunders, E.
71c86362-6926-4b2b-a8a2-07bb7617b4fa
Leongamornlert, D.
f4befc93-162d-48ba-a3db-a8954813ea64
Tymrakiewicz, M.
4179a470-13cd-47d6-a6e8-c17f6cb74618
Mahmud, N.
96b3afae-fd67-419b-9028-9d6993eeb734
Dadaev, T.
6b95b313-75f2-4e4d-9dbe-32f473df0ba7
Govindasami, K.
f6e4500c-d867-4067-b441-c3a6b5855217
Guy, M.
682e7cb4-f2b7-457c-ba8a-efa0155a918f
Sawyer, E.
e3ad320a-b2c4-4abf-802f-744ab07a65bc
Wilkinson, R.
93d60b91-c9fc-4de3-929b-cebbb412ee1a
Ardern-Jones, A.
615ce40c-596a-4b29-9578-13bf644aa3e0
Ellis, S.
e52868aa-0957-4f09-aa93-2bcd8ee03cfc
Frost, D.
aacda8ac-d343-4d95-a2d4-5c95a98072f2
Peock, S.
078d7af2-b419-40af-a52d-df59456d03b3
Evans, D.G.
b58c99fc-4da0-4d7e-b140-f22307befe5e
Tischkowitz, M.
d479aaea-0e4f-4f55-bc25-25fb599e7668
Cole, T.
5330af8b-76ec-4957-87b2-3aa3580a74c0
Davidson, R.
9f684474-a989-4d8c-988c-a42e3d19db25
Eccles, D.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Brewer, C.
f50e5721-93d3-43ef-8cd2-572f238d04be
Douglas, F.
9dc3db90-827e-419d-86f1-48e22b6845ab
Porteous, M.E.
e9bac242-13be-4b4b-bb8c-5ac6b8835e8c
Donaldson, A.
ea10ac5a-4f77-4ef5-91d5-7f32ea33db36
Dorkins, H.
c5c983b7-709c-4580-b98c-771a57aa31f0
Izatt, L.
5cabcdef-374a-4441-b571-9c7b1665b720
Cook, J.
45c40993-978e-496e-9922-65774f13985e
Hodgson, S.
745600cf-b91f-4f39-9b5e-4f76989d268f
Kennedy, M.J.
617fefc1-ee68-48ca-9fd6-66ef3733b442
Side, L.E.
35b06306-9246-4d20-887a-4472912fcf11
Eason, J.
8259442f-7b72-4b76-9a30-fa549384bbe0
Murray, A.
d80b2bea-5bde-448f-a1d2-c5627db1df99
Antoniou, A.C.
6dc040a0-bd30-4178-995b-ca6f237949e1
Easton, D.F.
ef4b7694-86fa-4568-969f-d0ee512127fc
Kote-Jarai, Z.
2d7fe076-52c9-4d83-b780-e85f8660ef05
Eeles, R.
c7ae2359-6f49-4f42-88f8-a241570f9d4f

Castro, E., Goh, C. and Olmos, D. et al. (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Journal of Clinical Oncology, 31 (14), 1748-1757. (doi:10.1200/JCO.2012.43.1882). (PMID:23569316)

Record type: Article

Abstract

PURPOSE: To analyze the baseline clinicopathologic characteristics of prostate tumors with germline BRCA1 and BRCA2 (BRCA1/2) mutations and the prognostic value of those mutations on prostate cancer (PCa) outcomes.

PATIENTS AND METHODS: This study analyzed the tumor features and outcomes of 2,019 patients with PCa (18 BRCA1 carriers, 61 BRCA2 carriers, and 1,940 noncarriers). The Kaplan-Meier method and Cox regression analysis were used to evaluate the associations between BRCA1/2 status and other PCa prognostic factors with overall survival (OS), cause-specific OS (CSS), CSS in localized PCa (CSS_M0), metastasis-free survival (MFS), and CSS from metastasis (CSS_M1).

RESULTS: PCa with germline BRCA1/2 mutations were more frequently associated with Gleason ? 8 (P = .00003), T3/T4 stage (P = .003), nodal involvement (P = .00005), and metastases at diagnosis (P = .005) than PCa in noncarriers. CSS was significantly longer in noncarriers than in carriers (15.7 v 8.6 years, multivariable analyses [MVA] P = .015; hazard ratio [HR] = 1.8). For localized PCa, 5-year CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93% v 77%; MVA P = .009; HR = 2.7, respectively). Subgroup analyses confirmed the poor outcomes in BRCA2 patients, whereas the role of BRCA1 was not well defined due to the limited size and follow-up in this subgroup.

CONCLUSION: Our results confirm that BRCA1/2 mutations confer a more aggressive PCa phenotype with a higher probability of nodal involvement and distant metastasis. BRCA mutations are associated with poor survival outcomes and this should be considered for tailoring clinical management of these patients.

This record has no associated files available for download.

More information

e-pub ahead of print date: 8 April 2013
Published date: 10 May 2013
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 383024
URI: http://eprints.soton.ac.uk/id/eprint/383024
ISSN: 1527-7755
PURE UUID: 347506f9-e1f9-40fe-a527-d9eeb7df6a39
ORCID for D. Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 19 Oct 2015 08:19
Last modified: 15 Mar 2024 02:40

Export record

Altmetrics

Contributors

Author: E. Castro
Author: C. Goh
Author: D. Olmos
Author: E. Saunders
Author: D. Leongamornlert
Author: M. Tymrakiewicz
Author: N. Mahmud
Author: T. Dadaev
Author: K. Govindasami
Author: M. Guy
Author: E. Sawyer
Author: R. Wilkinson
Author: A. Ardern-Jones
Author: S. Ellis
Author: D. Frost
Author: S. Peock
Author: D.G. Evans
Author: M. Tischkowitz
Author: T. Cole
Author: R. Davidson
Author: D. Eccles ORCID iD
Author: C. Brewer
Author: F. Douglas
Author: M.E. Porteous
Author: A. Donaldson
Author: H. Dorkins
Author: L. Izatt
Author: J. Cook
Author: S. Hodgson
Author: M.J. Kennedy
Author: L.E. Side
Author: J. Eason
Author: A. Murray
Author: A.C. Antoniou
Author: D.F. Easton
Author: Z. Kote-Jarai
Author: R. Eeles

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×